CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and ...
Keros Therapeutics, Inc. has three clinical stage programs targeting blood cells, blood vessels, and heart tissues by disrupting TGF-β signaling. Phase 2 data for their lead asset, KER-050, showed ...
A tissue section from a mouse model of lung metastasis showing cancer cells (green) that have attracted and activated fibroblasts (red) to support the growth of a metastatic tumor. Image: Massagué Lab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results